BIOMAT Database Logo BIOMAT Database Logo

In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis. 2005

Yunhua Chen, and Elizabeth Garber, and Qiuqu Zhao, and Yigong Ge, and Matthew A Wikler, and Koné Kaniga, and Lisa Saiman
Department of Pediatrics, Columbia University, 622 West 168th St., PH4W-470, New York, NY 10032, USA.

Doripenem 50% inhibitory concentrations (MIC50) and 90% inhibitory concentrations (MIC90) for multidrug-resistant strains of mucoid Pseudomonas aeruginosa (n=200 strains), nonmucoid P. aeruginosa (n=200), and Burkholderia cepacia complex (n=200) isolated from patients with cystic fibrosis were 8 and 32, 8 and 64, and 8 and 32 microg/ml, respectively. Doripenem had somewhat better activity than established antimicrobial agents.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D003550 Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION. Mucoviscidosis,Cystic Fibrosis of Pancreas,Fibrocystic Disease of Pancreas,Pancreatic Cystic Fibrosis,Pulmonary Cystic Fibrosis,Cystic Fibrosis, Pancreatic,Cystic Fibrosis, Pulmonary,Fibrosis, Cystic,Pancreas Fibrocystic Disease,Pancreas Fibrocystic Diseases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077726 Doripenem A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of infections such as HOSPITAL-ACQUIRED PNEUMONIA, and complicated intra-abdominal or urinary-tract infections, including PYELONEPHRITIS. 2-(5-sulfamoylaminomethylpyrrolidin-3-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapen-2-em-3-carboxylic acid,S 4661,S-4661,S4661
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D015780 Carbapenems A group of beta-lactam antibiotics in which the sulfur atom in the thiazolidine ring of the penicillin molecule is replaced by a carbon atom. THIENAMYCINS are a subgroup of carbapenems which have a sulfur atom as the first constituent of the side chain. Antibiotics, Carbapenem,Carbapenem,Carbapenem Antibiotics
D042602 Burkholderia cepacia complex A group of phenotypically similar but genotypically distinct species (genomovars) in the genus BURKHOLDERIA. They are found in water, soil, and the rhizosphere of crop plants. They can act as opportunistic human pathogens and as plant growth promoting and biocontrol agents.
D019121 Burkholderia Infections Infections with bacteria of the genus BURKHOLDERIA. B cepacia Infection,B. cepacia Infection,Burkholderia cepacia Infection,Burkholderia cepacia Sepsis,Infections, Burkholderia,B cepacia Infections,B. cepacia Infections,Burkholderia Infection,Burkholderia cepacia Infections,Burkholderia cepacia Sepses,Infection, B cepacia,Infection, B. cepacia,Infection, Burkholderia,Infection, Burkholderia cepacia,Infections, B cepacia,Sepses, Burkholderia cepacia,Sepsis, Burkholderia cepacia

Related Publications

Yunhua Chen, and Elizabeth Garber, and Qiuqu Zhao, and Yigong Ge, and Matthew A Wikler, and Koné Kaniga, and Lisa Saiman
In Vitro Activity of Ceftolozane-Tazobactam against Multidrug-Resistant Nonfermenting Gram-Negative Bacilli Isolated from Patients with Cystic Fibrosis.
April 2017, Antimicrobial agents and chemotherapy,
Yunhua Chen, and Elizabeth Garber, and Qiuqu Zhao, and Yigong Ge, and Matthew A Wikler, and Koné Kaniga, and Lisa Saiman
In vitro activity of arbekacin against multidrug-resistant gram-negative bacilli.
December 2021, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi,
Yunhua Chen, and Elizabeth Garber, and Qiuqu Zhao, and Yigong Ge, and Matthew A Wikler, and Koné Kaniga, and Lisa Saiman
Activity of disinfectants against Gram-negative bacilli isolated from patients undergoing lung transplantation for cystic fibrosis.
November 2002, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation,
Yunhua Chen, and Elizabeth Garber, and Qiuqu Zhao, and Yigong Ge, and Matthew A Wikler, and Koné Kaniga, and Lisa Saiman
Activities of doripenem (S-4661) against drug-resistant clinical pathogens.
August 2004, Antimicrobial agents and chemotherapy,
Yunhua Chen, and Elizabeth Garber, and Qiuqu Zhao, and Yigong Ge, and Matthew A Wikler, and Koné Kaniga, and Lisa Saiman
In vitro activity of fleroxacin against multiresistant gram-negative bacilli isolated from patients with nosocomial infections.
August 1998, Intensive care medicine,
Yunhua Chen, and Elizabeth Garber, and Qiuqu Zhao, and Yigong Ge, and Matthew A Wikler, and Koné Kaniga, and Lisa Saiman
In vitro activity of cefiderocol and comparator antibiotics against multidrug-resistant non-fermenting Gram-negative bacilli.
February 2024, JAC-antimicrobial resistance,
Yunhua Chen, and Elizabeth Garber, and Qiuqu Zhao, and Yigong Ge, and Matthew A Wikler, and Koné Kaniga, and Lisa Saiman
In vitro antibacterial activity of aminosterols against multidrug-resistant bacteria from patients with cystic fibrosis.
October 2009, The Journal of antimicrobial chemotherapy,
Yunhua Chen, and Elizabeth Garber, and Qiuqu Zhao, and Yigong Ge, and Matthew A Wikler, and Koné Kaniga, and Lisa Saiman
In vitro activity of cefiderocol against Gram-negative pathogens isolated from people with cystic fibrosis and bronchiectasis.
March 2024, Journal of global antimicrobial resistance,
Yunhua Chen, and Elizabeth Garber, and Qiuqu Zhao, and Yigong Ge, and Matthew A Wikler, and Koné Kaniga, and Lisa Saiman
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
February 2019, Drugs,
Yunhua Chen, and Elizabeth Garber, and Qiuqu Zhao, and Yigong Ge, and Matthew A Wikler, and Koné Kaniga, and Lisa Saiman
Mucoid gram-negative bacilli in cystic fibrosis.
March 1983, Lancet (London, England),
Copied contents to your clipboard!